You are hereFebruary 8, 2018
What’s the Stem Cells Buzz this Week? - Renal Regeneration without Stem Cells, Cell Therapy for Heart Failure, ASC Treatment for Sphincter Injury, and Expansion of UCB-HSPCs!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
In Situ Renal Tissue Regeneration
Stem cells and biomaterials make for a potent combination for tissue repair, but what if you didn’t need the stem cells? New research from the labs of Sang Jin Lee and James J. Yoo (Wake Forest School of Medicine, NC, USA) recently discovered that the injection of a collagen hydrogel into the kidney promoted the migration and infiltration of host stem cells into the biomaterial and the subsequent formation of kidney structures and recovery of lost function. To read more about this new research, head over to STEM CELLS Translational Medicine.
Cell Therapy for Right Ventricular Failure
While previous studies have tested the effect of CD34+ stem cell therapy on left ventricular (LV) function in patients with non-ischemic dilated cardiomyopathy (DCM), they did not assess for possible positive effects on right ventricular (LV) function. A new study from Bojan Vrtovec (Ljubljana University Medical Centre, Slovenia) now demonstrates that transendocardial injection of CD34+ stem cells collected from patients’ blood leads to significant improvements in RV function, which correlated with changes in the viability of the interventricular septum. See STEM CELLS Translational Medicine now for all the details on this new stem cell trial for heart failure.
Adipose Stem Cells in Rat Anal Sphincter Injury
A recent study from the laboratory of Kirsi Kuismanen (Tampere University, Finland) sought to assess the potential of adipose stem cell (ASC) injections to repair injuries to the anal sphincter that can lead to the development of anal incontinence. Encouragingly for sufferers of this devastating condition, the authors demonstrated that ASC injection was feasible and led to a significant improvement in muscle parameters in a rat model. STEM CELLS Translational Medicine has all the information on this encouraging animal study.
Expansion of UCB HSPC from MNC with Azole Compound
The ex vivo expansion of hematopoietic stem and progenitor cells (HSPC) from the umbilical cord blood (UCB) may boost regenerative potential; however, we currently lack an effective means to achieve this feat. Now, researchers from the lab of William Hwang Ying Khee (National Cancer Center Singapore) demonstrate that an azole compound, a novel structural analog of a p38-MAPK inhibitor, promotes the expansion of primitive HSPCs in UCB cultures. Furthermore, Bari et al. revealed that treated UCB cultures engrafted in the bone marrow and maintain functionality following transplantation into a mouse model. See STEM CELLS Translational Medicine now for all the fine print.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!